Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Glaus

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Regulatory Toxicology and Pharmacology : RTP|June 27, 2020
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fractureJames R Turk, Aimee M Deaton, Jun Yin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 8, 2019
Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical SpeciesRobert S Foti, Kaustav Biswas, Jennifer Aral, et al.
ACS Chemical Biology|March 16, 2019
Engineering Na<sub>V</sub>1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance PharmacokineticsJustin K Murray, Bin Wu, Christopher M Tegley, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Regulatory Toxicology and Pharmacology : RTP|June 27, 2020
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fractureJames R Turk, Aimee M Deaton, Jun Yin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 8, 2019
Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical SpeciesRobert S Foti, Kaustav Biswas, Jennifer Aral, et al.
ACS Chemical Biology|March 16, 2019
Engineering Na<sub>V</sub>1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance PharmacokineticsJustin K Murray, Bin Wu, Christopher M Tegley, et al.
Pageof 2